CEPI And EU Grant Valneva $41.3M To Enhance Global Reach Of Chikungunya Vaccine IXCHIQ
Portfolio Pulse from Benzinga Newsdesk
Valneva has secured up to $41.3 million from CEPI and the European Union to expand access to its chikungunya vaccine, IXCHIQ®. The funding will support clinical trials in vulnerable groups and technology transfer to an additional manufacturer for supply to Asian LMICs. IXCHIQ® is already approved for adults in the U.S., Canada, and Europe.
July 22, 2024 | 6:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Valneva has received up to $41.3 million from CEPI and the EU to enhance the global reach of its chikungunya vaccine, IXCHIQ®. This funding will support clinical trials in vulnerable groups and technology transfer to an additional manufacturer for supply to Asian LMICs. IXCHIQ® is already approved for adults in the U.S., Canada, and Europe.
The funding from CEPI and the EU is significant for Valneva as it will enable the company to expand the reach of its chikungunya vaccine, IXCHIQ®. This includes conducting clinical trials in vulnerable groups and facilitating technology transfer to an additional manufacturer, which could lead to increased production and distribution, particularly in Asian LMICs. The approval of IXCHIQ® in major markets like the U.S., Canada, and Europe further strengthens its market position.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100